These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Tremollieres F; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Vujovic S; Rozenberg S; Rees M; Maturitas; 2011 Jun; 69(2):195-8. PubMed ID: 21489728 [TBL] [Abstract][Full Text] [Related]
3. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY; Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339 [TBL] [Abstract][Full Text] [Related]
6. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Douketis JD; Ginsberg JS; Holbrook A; Crowther M; Duku EK; Burrows RF Arch Intern Med; 1997 Jul; 157(14):1522-30. PubMed ID: 9236553 [TBL] [Abstract][Full Text] [Related]
7. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study. Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D; Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158 [TBL] [Abstract][Full Text] [Related]
8. Risk of venous thromboembolism in users of hormone replacement therapy. Daly E; Vessey MP; Hawkins MM; Carson JL; Gough P; Marsh S Lancet; 1996 Oct; 348(9033):977-80. PubMed ID: 8855852 [TBL] [Abstract][Full Text] [Related]
9. The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study. Douketis JD; Julian JA; Crowther MA; Kearon C; Bates SM; Barone M; Piovella F; Middeldorp S; Prandoni P; Johnston M; Costantini L; Ginsberg JS Clin Appl Thromb Hemost; 2011; 17(6):E106-13. PubMed ID: 21159708 [TBL] [Abstract][Full Text] [Related]
10. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. L'Hermite M Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491 [TBL] [Abstract][Full Text] [Related]
11. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Le Gal G; Kovacs MJ; Carrier M; Do K; Kahn SR; Wells PS; Anderson DA; Chagnon I; Solymoss S; Crowther M; Righini M; Lacut K; White RH; Vickars L; Rodger M Thromb Haemost; 2010 Sep; 104(3):498-503. PubMed ID: 20539910 [TBL] [Abstract][Full Text] [Related]
12. Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Waselenko JK; Nace MC; Alving B Semin Thromb Hemost; 1998; 24 Suppl 1():33-9. PubMed ID: 9840690 [TBL] [Abstract][Full Text] [Related]
13. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311 [TBL] [Abstract][Full Text] [Related]